Cited by 619Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesHematopoietic Stem Cell Transplantation

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Open access

Burnett, Alan K., Milligan, Donald, Prentice, Archie G., Goldstone, Anthony H., McMullin, Mary F., Hills, Robert K., Wheatley, Keith·2007·Cancer

DOI 10.1002/cncr.22496

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The survival of older patients with acute myeloid leukemia has not improved. Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach. METHODS: Between December 1998 and November 2003, as part of National Cancer Research Institute Acute Myeloid Leukemia 14 Trial, 217 patients, who were deemed unfit for intensive chemotherapy were randomized to receive low‐dose cytarabine (Ara‐C) (20 mg twice daily for 10 days) or hydroxyurea with or without all‐trans retinoic acid (ATRA). RESULTS: Low‐dose ara‐C produced a better remission rate (18% vs 1%; odds ratio [OR], 0.15; 95% confidence interval [95% CI], 0.06–0.37; P = .00006) and better overall survival (OR, 0.60; 95% CI, 0.44–0.81; P = .0009), which was accounted for by the achievement of complete remission (CR) (duration of CR: 80 weeks vs 10 weeks for patients with no CR). Patients who had adverse cytogenetics did not benefit. ATRA had no effect. Toxicity scores or supportive care requirements did not differ between the treatment arms. CONCLUSIONS: Older, less fit patients have a poor outcome, and few trials have been conducted in this patient group. Low‐dose ara‐C treatment was superior to best supportive care and hydroxyurea because it had greater success in achieving CR, and it could represent standard care against which new treatments may be compared in this patient group. [See editorial on pages 000–000, this issue.] Cancer 2007 © 2007 American Cancer Society.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cncr.22496

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
Campos, L., Rouault, J., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J., & Guyotat, D. (1993) · Blood · doi:10.1182/blood.v81.11.3091.3091 · Cited by 783
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 608
On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.
Löwenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Cauchie, C., Peetermans, M. E., Solbu, G., & Suciu, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1268 · Cited by 383
The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly
Menzin, J., Lang, K., Earle, C. C., Kerney, D. L., & Mallick, R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1597 · Cited by 276
Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
Tilly, H., Castaigné, S., Bordessoule, D., Casassus, P., Prisé, P. Y. L., Tertian, G., Desablens, B., Henry-Amar, M., & Degos, L. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.2.272 · Cited by 259
A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
Cheson, B. D., Jasperse, D. M., Simon, R. M., & Friedman, M. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.12.1857 · Cited by 210
Small doses of ARA‐C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells?
Housset, M., Daniel, M., & Degos, L. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb07297.x · Cited by 189
Response of Preleukemic Syndromes to Continuous Infusion of Low-Dose Cytarabine
Wisch, J. S., Griffin, J. D., & Kufe, D. W. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312293092602 · Cited by 179
Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid
Andreeff, M., Jiang, S., Zhang, X., Konopleva, M. Y., Estrov, Z. E., Snell, V., Xie, Z., Okcu, M., Sanchez‐Williams, G., Dong, J., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401573 · Cited by 153
Sexual functioning morbidity among cancer survivors. Current status and future research directions
Andersen, B. L. (1985) · Cancer · doi:10.1002/1097-0142(19850415)55:8 · Cited by 147

Show all 26 references

Sorted by citations

Items 301–400 of 619

Myelodysplastic Syndromes—Many New Drugs, Little Therapeutic Progress
Tefferi, A. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0502 · Cited by 17
Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus.
Brandwein, J. M., Geddes, M. N., Kassis, J., Kew, A. K., Leber, B. F., Nevill, T. J., Sabloff, M., Sandhu, I., Schuh, A. C., Storring, J. M., et al. (2013) · Europe PMC (PubMed Central) · Cited by 16
Initial therapy for acute myeloid leukemia in older patients: principles of care
Bhatt, V. R., Gundabolu, K., Koll, T. T., & Maness, L. J. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1323275 · Cited by 16
Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
Duong, H., & Sekeres, M. A. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s3968 · Cited by 16
Clofarabine in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Older Adults
Tran, H., & Yang, D. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q295 · Cited by 16
Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia
Liberante, F. G., Pouryahya, T., McMullin, M., Zhang, S., & Mills, K. (2015) · Oncotarget · doi:10.18632/oncotarget.6773 · Cited by 16
Self-citation
A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
Schliemann, C., Gerß, J., Wiebe, S., Mikesch, J., Knoblauch, N. T. M., Sauer, T., Angenendt, L., Kewitz, T., Urban, M., Butterfaß‐Bahloul, T., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164499 · Cited by 15
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo
Schnerch, D., Schüler, J. B., Follo, M., Felthaus, J., Wider, D., Klingner, K., Greil, C., Duyster, J., Engelhardt, M. M., & Wäsch, R. (2017) · Oncotarget · doi:10.18632/oncotarget.15503 · Cited by 15
Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1
Paubelle, É., Pleșa, A., Hayette, S., Elhamri, M., Zylbersztejn, F., Hermine, O., Salles, G. A., & Thomas, X. (2019) · Oncology and Therapy · doi:10.1007/s40487-019-0095-9 · Cited by 16
Acute Myeloid Leukemia: Update on Upfront Therapy in Elderly Patients
Keiffer, G., & Palmisiano, N. D. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0823-1 · Cited by 15
Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma
Lejeune, M., & Álvaro, T. (2008) · Haematologica · doi:10.3324/haematol.2008.001255 · Cited by 15
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia
Walter, R. B., Michaelis, L. C., Othus, M. K. D., Uy, G. L., Radich, J. P., Little, R. F., Hita, S., Saini, L., Foran, J. M., Gerds, A. T., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24980 · Cited by 15
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
Ritchie, E. K. (2012) · Clinical Interventions in Aging · doi:10.2147/cia.s24659 · Cited by 15
A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
Gemici, A. İ., Özkalemkaş, F., Doğu, M. H., Tekinalp, A., Alacacıoğlu, İ., Güney, T., İnce, İ., Gedük, A., Çağlıyan, G. A., Maral, S., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.04.004 · Cited by 14
Decitabine for acute myeloid leukemia
Marks, P. W. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.207 · Cited by 14
Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid
Hernandez-Valladares, M., Wangen, R., Aasebø, E., Reikvam, H., Berven, F. S., Selheim, F., & Bruserud, Ø. (2021) · Cancers · doi:10.3390/cancers13092143 · Cited by 14
The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
Piccini, M., Mannelli, F., & Coltro, G. (2023) · Bioengineering · doi:10.3390/bioengineering10050591 · Cited by 14
Update on Optimal Management of Acute Myeloid Leukemia
Rassi, F. A. E., & Arellano, M. L. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s8528 · Cited by 14
A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis
Minakata, D., Fujiwara, S., Ito, S., Mashima, K., Umino, K., Nakano, H., Kawasaki, Y., Sugimoto, M., Yamasaki, R., Yamamoto, C., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2015.12.013 · Cited by 14
Effects of 5′,8-Cyclodeoxyadenosine Triphosphates on DNA Synthesis
Kamakura, N., Yamamoto, J., Brooks, P. J., Iwai, S., & Kuraoka, I. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300351p · Cited by 14
How I treat older patients with acute myeloid leukemia
Arellano, M. L., & Carlisle, J. W. (2018) · Cancer · doi:10.1002/cncr.31347 · Cited by 14
Amsacrine containing induction therapy in elderly AML patients: Comparison to standard induction regimens in a matched-pair analysis
Keßler, T., Möhr, M., Müller‐Tidow, C., Krug, U. O., Brunnberg, U., Mohr, B., Schliemann, C., Sauerland, C., Serve, H. L., Büchner, T., et al. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.06.015 · Cited by 14
Intensive Chemotherapy in Patients Aged 70 Years or Older Newly Diagnosed With Acute Myeloid Leukemia
Ross, K. G., Gillespie-Twardy, A. L., Agha, M., Raptis, A., Hou, J., Farah, R., Redner, R. L., Im, A., Duggal, S., Ding, F., et al. (2015) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504014x14146137738547 · Cited by 14
Therapy for elderly patients with acute myeloid leukemia
Kantarjian, H. M. (2007) · Cancer · doi:10.1002/cncr.22502 · Cited by 14
Chemotherapy options for previously untreated acute myeloid leukemia
Lynch, R. C., & Medeiros, B. C. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1076795 · Cited by 13
Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review
Bell, J. A., Galaznik, A., Huelin, R., Stokes, M., Guo, Y., Fram, R. J., & Faller, D. V. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.05.003 · Cited by 13
Optimizing management of acute leukemia in community centers and when to refer
Jillella, A. P., Cortes, J. E., & Kota, V. K. (2020) · Hematology · doi:10.1182/hematology.2020000096 · Cited by 13
Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia
Kang, J.-B., Chen, L., Leng, X., Wang, J., Yang, C., Wu, S.-H., Ma, Y.-Y., Yang, L.-J., Cao, Y., Yang, X. C., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116937 · Cited by 14
Paradigm Shift in the Management of Acute Myeloid Leukemia—Approved Options in 2023
Premnath, N., & Madanat, Y. F. (2023) · Cancers · doi:10.3390/cancers15113002 · Cited by 13
Economic analysis of blood product transfusions according to the treatment of acute myeloid leukemia in the elderly
Cannas, G., Fattoum, J., Boukhit, M., & Thomas, X. (2015) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2015.06.249 · Cited by 13
High‐dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years
Arellano, M. L., Winton, E. F., Pan, L., Lima, L. M., Tighiouart, M., Bhalla, K. N., Heffner, L. T., Neely, J. J., Hutcherson, D. A., McLemore, M. L., et al. (2011) · Cancer · doi:10.1002/cncr.26290 · Cited by 13
Recent advances in the treatment of acute myeloid leukemia
Abdel-Wahab, O. I., & Levine, R. L. (2010) · F1000 Medicine Reports · doi:10.3410/m2-55 · Cited by 13
Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience
Heiblig, M., Jeune, C. L., Elhamri, M., Balsat, M., Tigaud, I., Pleșa, A., Barraco, F., Labussière, H., Ducastelle, S., Nicolini, F. E., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1180688 · Cited by 13
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies
Norsworthy, K. J., Cho, E., Arora, J. K., Kowalski, J., Tsai, H., Warlick, E. D., Showel, M. M., Pratz, K. W., Sutherland, L., Gore, S. D., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.09.003 · Cited by 14
Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia
Al‐Ali, H. K., Cross, M. A., Bach, E., Krahl, R., Jaekel, N., Niederwieser, D. W., Junghanß, C., Maschmeyer, G., & Tran (2013) · OncoTargets and Therapy · doi:10.2147/ott.s45459 · Cited by 13
Information needs, decisional regret and satisfaction of older and younger adults with acute myeloid leukemia
Mohamedali, H. Z., Breunis, H., Panju, A. H., & Alibhai, S. M. H. (2010) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2010.06.002 · Cited by 13
Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study
Budziszewska, B. K., Pluta, A., Sułek, K., Wierzbowska, A., Robak, T., Giebel, S., Holowiecka-Goral, A. M., Sawicki, W., Ejduk, A., Patkowska, E., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.985672 · Cited by 13
Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy
Shin, S., Cho, B., Park, S., Cho, S., Jeon, Y., Yoon, J., Yahng, S., Lee, S., Lee, D., Eom, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23629 · Cited by 12
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens
Baden, D., Zukunft, S., Hernández, G., Wolgast, N., Steinhäuser, S. S., Pohlmann, A., Schliemann, C., Mikesch, J., Steffen, B., Sauer, T., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.285225 · Cited by 12
Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
DeAngelo, D. J., Stein, E. M., & Ravandi, F. (2016) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbk_161258 · Cited by 12
BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study
Zuckerman, T., Ram, R., Akria, L., Koren‐Michowitz, M., Hoffman, R., Henig, I. J., Lavi, N., Ofran, Y., Horowitz, N. A., Nudelman, O., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000468 · Cited by 12
IGFBP7 activates retinoid acid–induced responses in acute myeloid leukemia stem and progenitor cells
van Gils, N., Verhagen, H. J. M. P., Rutten, A. P., de Menezes, R. X., Tsui, M.-L., Vermue, E., Dekens, E., Brocco, F., Denkers, F., Kessler, F. L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002812 · Cited by 11
Gemtuzumab ozogamicin as first‐line treatment in patients aged 70 years or older with acute myeloid leukemia
McHayleh, W. M., Foon, K. A., Redner, R. L., Sehgal, R., Raptis, A., Agha, M., Luong, T. M., Schlesselman, J. J., & Boyiadzis, M. M. (2010) · Cancer · doi:10.1002/cncr.25078 · Cited by 12
Therapy of older persons with acute myeloid leukaemia
Krug, U. O., Gale, R. P., Berdel, W. E., Müller‐Tidow, C., Stelljes, M., Metzeler, K. H., Sauerland, M. C., Hiddemann, W., & Büchner, T. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.05.020 · Cited by 12
Clinical Manifestations and Treatment of Acute Myeloid Leukemia
Faderl, S., & Kantarjian, H. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00059-7 · Cited by 12
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
Ayala, R. M., Rapado, I., Onecha, E., Martínez‐Cuadrón, D., Carreño‐Tarragona, G., Bergua, J., Vives, S., Algarra, J. L., Tormo, M., Martı́nez, P., et al. (2021) · Cancers · doi:10.3390/cancers13102458 · Cited by 12
Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia
Hütter, M.-L., & Schlenk, R. F. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.604630 · Cited by 11
Treatment of Acute Myeloid Leukemia in Elderly Patients—A Therapeutic Dilemma
Mamdani, H. M., Santos, C. D., & Koenig, H. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.03.001 · Cited by 11
New Treatment Options for Older Patients with Acute Myeloid Leukemia
Saxena, K., & Konopleva, M. Y. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00841-4 · Cited by 11
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia
Sasaki, K., Ravandi, F., Kadia, T. M., Borthakur, G. M., Short, N. J., Jain, N., Daver, N. G., Jabbour, E. J., Garcia‐Manero, G., Loghavi, S., et al. (2023) · Cancer · doi:10.1002/cncr.34609 · Cited by 11
Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients
Jamieson, K. J., & Lim, M. Y. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s39558 · Cited by 11
Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Fukushima, T., Kawabata, H., Sawaki, T., Satoh, T., Nakamura, T., Iwao, H. K., Nakajima, A., Sakai, T., Miki, M., Fujita, Y., et al. (2012) · PubMed · Cited by 11
RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis
Zebisch, A., Caraffini, V., & Sill, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225756 · Cited by 11
Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?
Chen, E. C., & Garcia, J. S. (2020) · Hematology · doi:10.1182/hematology.2020000087 · Cited by 11
Spectrum of infections in different regimens of post-induction chemotherapy in acute myeloid leukemia (de-novo): A comparative retrospective study
Majid, H., Masoom, M., Bansal, N., Ahmad, W., Khan, M. F., Farooqui, S., Bhurani, D., & Khan, M. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24561 · Cited by 10
Intensive Chemotherapy Versus Venetoclax-Based Regimens in Elderly Patients with Acute Myeloid Leukemia: Is the Chemotherapy Era Ending?
Farina, M., Malagola, M., Bernardi, S., Re, F., Russo, D., & Avenoso, D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082759 · Cited by 10
Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia
Schlenk, R. F., Weber, D., Krzykalla, J., Kindler, T., Wulf, G. G., Hertenstein, B., Salih, H. R., Südhoff, T., Krauter, J., Martens, U. M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41964-y · Cited by 10
Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules
Banchi, M., Cox, M. C., & Bocci, G. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216900 · Cited by 10
Clofarabine: a new treatment option for patients with acute myeloid leukemia
Larson, M. L., & Venugopal, P. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902997990 · Cited by 10
Clinicopathologic features and outcome of acute erythroid leukemia based on 2008 revised World Health Organization classification
Liu, C., Hong, Y., Yang, C., Liu, S.-H., Gau, J., Liu, H., Hsiao, L., Liu, C., Yu, Y., & Tzeng, C. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.607526 · Cited by 10
Metronomic therapy with oral 6-mercaptopurine in elderly acute myeloid leukemia: A prospective pilot study
Kapoor, A., Beniwal, S. K., Kalwar, A., Singhal, M. K., Nirban, R. K., & Kumar, H. S. (2016) · South Asian Journal of Cancer · doi:10.4103/2278-330x.181644 · Cited by 10
All‐trans retinoic acid (ATRA) in non‐promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low‐dose Ara‐C in three elderly patients with NPM1‐mutated AML unfit for intensive chemotherapy and review of the literature
Forghieri, F., Bigliardi, S., Quadrelli, C., Morselli, M., Potenza, L., Paolini, A., Colaci, E., Barozzi, P., Zucchini, P., Riva, G., et al. (2016) · Clinical Case Reports · doi:10.1002/ccr3.723 · Cited by 10
An Integrative multi-lineage model of variation in leukopoiesis and acute myelogenous leukemia
Sarker, J. M., Pearce, S. M., Nelson, R. P., Kinzer‐Ursem, T. L., Umulis, D. M., & Rundell, A. E. (2017) · BMC Systems Biology · doi:10.1186/s12918-017-0469-2 · Cited by 10
Acute Myeloid Leukemia in Adults
Versluis, J., Cornelissen, J. J., Craddock, C., Sanz, M. Á., Canaani, J., & Nagler, A. (2018) · Springer eBooks · doi:10.1007/978-3-030-02278-5_69 · Cited by 12
Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients—a real-world experience from India
Kanakasetty, G. B., Chethan, R., Lakshmaiah, K., Dasappa, L., Jacob, L. A., C., S. B. M., Lokesh, K. N., Haleshappa, R. A., Rajeev, L. K., Saldanha, S., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03600-6 · Cited by 10
The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
Assouline, S. E., Cocolakis, E., & Borden, K. L. B. (2012) · Cancers · doi:10.3390/cancers4041161 · Cited by 10
The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline
Leitch, H. A., Buckstein, R. J., Shamy, A., & Storring, J. M. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.07.003 · Cited by 10
Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
Bashir, Y., Geelani, S., Bashir, N., Mir, S. A., Mushtaq, M., Jan, M. A., & Rasool, J. (2015) · South Asian Journal of Cancer · doi:10.4103/2278-330x.149918 · Cited by 10
Prognostic factors and treatment outcome in 1,516 adult patients with de novo and secondary acute myeloid leukemia in 1999–2009 in 5 hematology intensive care centers in the Czech Republic
Szotkowski, T., Mužı́k, J., Voglová, J., Koza, V., Maaloufová, J., Kozák, T., Jarošová, M., Michalova, K., Зак, П., Steinerová, K., et al. (2010) · Neoplasma · doi:10.4149/neo_2010_06_578 · Cited by 10
The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia
Cooperrider, J. H., Shukla, N., Nawas, M. T., & Patel, A. A. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00342 · Cited by 10
Azacitidine and low‐dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts – a retrospective single‐center experience
Radujkovic, A., Dietrich, S., Bochtler, T., Krämer, A., Schöning, T., Ho, A. D., Dreger, P., & Luft, T. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12308 · Cited by 9
Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature
Wolleschak, D., Schalk, E., Krogel, C., Schnoeder, T. M., Luehr, H., Jentsch‐Ullrich, K., Fischer, T., & Heidel, F. H. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-39 · Cited by 9
Optimal sequencing of treatments for patients with myelodysplastic syndromes
Itzykson, R., & Fenaux, P. (2009) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283257a74 · Cited by 9
Clinical and epidemiological characteristics of acute myeloid leukemias in adults according to the data of municipal hematology departments in Moscow
Семочкин, С. В., Толстых, Т. Н., Архипова, Н. В., Ivanova, V., Клюева, О. В., Лунин, В. В., Misyurina, E. N., Туманова, М. В., & Хуажева, Н. К. (2015) · Terapevticheskii arkhiv · doi:10.17116/terarkh201587726-32 · Cited by 9
The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia
Paubelle, É., Zylbersztejn, F., & Thomas, X. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1331215 · Cited by 9
The management and treatment of acute leukemias in the elderly population
Thomas, X. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1382345 · Cited by 9
Incorporating newer agents in the treatment of acute myeloid leukemia
Raj, R. V., Abedin, S. M., & Atallah, E. L. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.10.008 · Cited by 9
A randomised evaluation of low‐dose cytosine arabinoside (ara‐C) plus tosedostat versus low‐dose ara‐C in older patients with acute myeloid leukaemia: results of the LI‐1 trial
Dennis, M., Burnett, A. K., Hills, R. K., Thomas, I., Ariti, C. A., Severinsen, M. T., Hemmaway, C. J., Greaves, P., Clark, R. E., Copland, M., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17501 · Cited by 9
Self-citation
The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs
Short, N. J., Dombret, H., Adès, L., & Kantarjian, H. M. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000568 · Cited by 9
Acute Myeloid Leukemia
Klepin, H. D., & Pardee, T. S. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2837-3_4 · Cited by 9
Outcome of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome According to Health Insurance Status
Al-Ameri, A., Anand, A., Abdelfatah, M. M., Kanaan, Z., Hammonds, T. L., Haller, N. A., & Cherry, M. A. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.03.003 · Cited by 9
Clomiphene as a novel modality for the treatment of acute myeloid leukemia: A pilot phase II study
Yom-Tov, G., Nathan, I., Shpilberg, O., Polliack, A., & Levi, I. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.08.015 · Cited by 9
Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome
Roboz, G. J., Ritchie, E. K., Curcio, T. J., Samuel, M., Provenzano, J. L., Segovia, J. M., Christos, P. J., Mathew, S., Allen‐Bard, S., & Feldman, E. J. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.09.010 · Cited by 9
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
Roboz, G. J., Wissa, U., Ritchie, E. K., Gergis, U. S., Mayer, S. A., Scandura, J. M., Christos, P. J., & Feldman, E. J. (2012) · Leukemia Research · doi:10.1016/j.leukres.2011.12.019 · Cited by 9
Selection of Elderly Acute Myeloid Leukemia Patients for Intensive Chemotherapy: Effectiveness of Intensive Chemotherapy and Subgroup Analysis
Kim, D. S., Kang, K., Yu, E. S., Kim, H. J., Kim, J. S., Lee, S. R., Park, Y., Sung, H. J., Yoon, S. Y., Choi, C. W., et al. (2014) · Acta Haematologica · doi:10.1159/000362777 · Cited by 9
Levels of Care: Defining Best Supportive Care in Elderly Patients with Acute Myeloid Leukemia
Ritchie, E. K., & Roboz, G. J. (2010) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-010-0048-8 · Cited by 9
All-trans retinoic acid beyond acute promyelocytic leukemia
Rehman, U., & Lübbert, M. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.008 · Cited by 8
Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper
Dennis, M., Copland, M., Kaur, H., Kell, J., Nikolousis, E., Mehta, P., Palanicawandar, R., Potter, V. T., Raj, K. K., Thomas, I., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18369 · Cited by 8
Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?
Marvin‐Peek, J., Gilbert, J. S., Pollyea, D. A., & Dinardo, C. D. (2024) · American Journal of Hematology · doi:10.1002/ajh.27434 · Cited by 8
The euphoria of hypomethylating agents in MDS and AML: Is it justified?
Sekeres, M. A. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.10.001 · Cited by 8
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older
Vives, S., Oriol, A., Piernas, S., Brunet, S., Clapés, V., Guàrdia, R., Subirá, M., Sierra, J., Ribera, J., & the CETLAM Group (2015) · European Journal Of Haematology · doi:10.1111/ejh.12538 · Cited by 8
THE CHALLENGE OF AML IN OLDER PATIENTS
Burnett, A. K. (2013) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2013.038 · Cited by 8
Self-citation
Clinical Trial Outcomes
Martinez, R. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2018.12.003 · Cited by 8
Non-intensive acute myeloid leukemia therapies for older patients
Babakhanlou, R., & Ravandi, F. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2184342 · Cited by 8
The Efficacy of the Ribonucleotide Reductase Inhibitor Didox in Preclinical Models of AML
Cook, G., Caudell, D. L., Elford, H. L., & Pardee, T. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112619 · Cited by 8
Treatment of Older Patients With Newly Diagnosed AML Unfit for Traditional Therapy
Burnett, A. K. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.06.027 · Cited by 8
Self-citation
A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies
Mosialou, I., Ali, A. M., Labella, R., Bisikirska, B. C., Cuesta‐Domínguez, Á., Vgenopoulou, P., Reyes, I., Rao, S. M., Wang, A., Luo, N., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.007 · Cited by 8
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia
Prescott, H., Kantarjian, H. M., Cortes, J. E., & Ravandi, F. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.568938 · Cited by 7
Importance of prognostic stratification via gene mutation analysis in elderly patients with acute myelogenous leukemia
Fujiwara, Y., Yamaguchi, H., Yui, S., Tokura, T., Inai, K., Onai, D., Omori, I., Marumo, A., Yamanaka, S., Sakaguchi, M., et al. (2019) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13025 · Cited by 7
Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation: a network meta-analysis
Wang, L., Song, J., Xiao, X., Li, D., Liu, T., & He, X. (2023) · Journal of Chemotherapy · doi:10.1080/1120009x.2023.2247200 · Cited by 7

Authors: Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K.
Affiliations: Cardiff University (GB)
Heartlands Hospital (GB)
Derriford Hospital (GB)
University College Hospital (GB)
Belfast City Hospital (GB)
Cancer Research UK Clinical Trials Unit (GB)
Corresponding author: Burnett, Alan K.
ORCID: Burnett, Alan K.
Goldstone, Anthony H.
McMullin, Mary F.
Hills, Robert K.
Wheatley, Keith
Venue: Cancer
Publisher: Wiley
Published: 2007-02-21
Volume: 109
Issue: 6
Pages: 1114-1124
ISSN: 0008-543X (ISSN-L)
1097-0142
DOI: 10.1002/cncr.22496
OpenAlex: W2068556430
Cited by: 619
References: 26
Citations by year: 2026: 5 · 2025: 14 · 2024: 13 · 2023: 23 · 2022: 28 · 2021: 43 · 2020: 45 · 2019: 40 · 2018: 29 · 2017: 37 · 2016: 36 · 2015: 54 · 2014: 48 · 2013: 42 · 2012: 36
FWCI: 18.95
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Cancer (publishedVersion)
PubMed (publishedVersion)
ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Research Portal (Queen's University Belfast) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords: acute myeloid leukemia, high-risk myelodysplastic syndrome, low-dose cytarabine, hydroxyurea, all-trans retinoic acid, elderly patients, complete remission, overall survival, adverse cytogenetics, best supportive care
MeSH terms: Acute Disease, Aged, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Female, Humans, Hydroxyurea, Leukemia, Myeloid, Male, Middle Aged, Myelodysplastic Syndromes, Risk, Survival, Tretinoin, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks